Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nezam H Afdhal

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
Hepatology (Baltimore, Md.)|January 22, 2011
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment responseJama M Darling, Jeroen Aerssens, Gregory Fanning, et al.
The New England Journal of Medicine|April 9, 2010
Telaprevir for previously treated chronic HCV infectionJohn G McHutchison, Michael P Manns, Andrew J Muir, et al.
The New England Journal of Medicine|September 16, 2011
Response-guided telaprevir combination treatment for hepatitis C virus infectionKenneth E Sherman, Steven L Flamm, Nezam H Afdhal, et al.
Journal of Hepatology|August 26, 2018
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment optionsZobair Younossi, Maria Stepanova, Arun J Sanyal, et al.
Hepatology (Baltimore, Md.)|October 20, 2012
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trialMark S Sulkowski, Fred Poordad, Michael P Manns, et al.
Gastroenterology|June 15, 2016
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and SofosbuvirChristoph Sarrazin, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.
Gastroenterology|August 21, 2010
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rateMark S Sulkowski, Mitchell L Shiffman, Nezam H Afdhal, et al.
Hepatology (Baltimore, Md.)|April 18, 2019
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab TrialsArun J Sanyal, Stephen A Harrison, Vlad Ratziu, et al.
Hepatology (Baltimore, Md.)|August 29, 2018
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the DiseaseAndrew J Muir, Cynthia Levy, Harry L A Janssen, et al.
Hepatology Communications|December 2, 2024
Serum protein risk stratification score for diagnostic evaluation of metabolic dysfunction-associated steatohepatitisMichelle Lai, Simon T Dillon, Xuesong Gu, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
Hepatology (Baltimore, Md.)|January 22, 2011
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment responseJama M Darling, Jeroen Aerssens, Gregory Fanning, et al.
The New England Journal of Medicine|April 9, 2010
Telaprevir for previously treated chronic HCV infectionJohn G McHutchison, Michael P Manns, Andrew J Muir, et al.
The New England Journal of Medicine|September 16, 2011
Response-guided telaprevir combination treatment for hepatitis C virus infectionKenneth E Sherman, Steven L Flamm, Nezam H Afdhal, et al.
Journal of Hepatology|August 26, 2018
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment optionsZobair Younossi, Maria Stepanova, Arun J Sanyal, et al.
Hepatology (Baltimore, Md.)|October 20, 2012
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trialMark S Sulkowski, Fred Poordad, Michael P Manns, et al.
Gastroenterology|June 15, 2016
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and SofosbuvirChristoph Sarrazin, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.
Gastroenterology|August 21, 2010
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rateMark S Sulkowski, Mitchell L Shiffman, Nezam H Afdhal, et al.
Hepatology (Baltimore, Md.)|April 18, 2019
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab TrialsArun J Sanyal, Stephen A Harrison, Vlad Ratziu, et al.
Hepatology (Baltimore, Md.)|August 29, 2018
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the DiseaseAndrew J Muir, Cynthia Levy, Harry L A Janssen, et al.
Hepatology Communications|December 2, 2024
Serum protein risk stratification score for diagnostic evaluation of metabolic dysfunction-associated steatohepatitisMichelle Lai, Simon T Dillon, Xuesong Gu, et al.
Pageof 12